Back to School: How biopharma can reboot drug development. Access exclusive analysis here
IMCLE was off $0.14 to $38.39 on 19.9 million shares despite reporting Thursday after
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury